Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€4.34

€4.34

-5.160%
-0.236
-5.160%
€6.00

€6.00

 
19.01.22 / Frankfurt WKN: A14M04 / Name: Poxel / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
€6.00
24.11.21
-19.14%
buy
Your prediction

Poxel S.A. Stock

Heavy losses for Poxel S.A. today as the stock fell by -€0.236 (-5.160%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Poxel S.A. stock is not clear.
As a result the target price of €6.00 shows a positive potential of 38.185% compared to the current price of €4.34 for Poxel S.A..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Poxel S.A. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Poxel S.A. in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Poxel S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Poxel S.A. -5.160% -5.072% -13.420% -39.945% -11.532% -16.500% -37.145%
Quantum Genomics S.A. -2.680% 0.048% 1.742% -14.163% 2.137% - -
Innate Pharma 4.880% -2.594% -10.481% -1.241% -5.955% -44.140% -73.262%
Erytech Pharma S.A. -4.650% -1.887% 1.961% - -0.716% - -

Comments

Prediction Sell
Perf. (%) 56.92%
Target price
Change
Ends at 29.01.20

Sell beendet
Show more

Sell Poxel S.A.
Show more

Prediction Buy
Perf. (%) -21.69%
Target price 9.000
Change
Ends at 04.11.21

Buy with target price 9.0
Show more

Other discussions about Poxel S.A. Stock

New thread Forum

News

Poxel Announces Financial Calendar for 2022: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces Financial Calendar for 2022


POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic

Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022


POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including

Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases


POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic